Uses of topiramate in the treatment of alcohol dependence

Expert Review of Neurotherapeutics

Volumn 4, Issue 5, 2004, Pages 751-758

  Johnson, Bankole A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Alcohol dependence; Anticonvulsant; Craving; Pharmacotherapy; Topiramite

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ACETAZOLAMIDE; AMITRIPTYLINE; DISULFIRAM; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE; RISPERIDONE; TOPIRAMATE;

ACIDOSIS; ALCOHOLISM; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONCENTRATION LOSS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; HUMAN; HYPERTHERMIA; INTRAOCULAR HYPERTENSION; MEMORY DISORDER; MYOPIA; NEPHROLITHIASIS; NEUROMODULATION; PARESTHESIA; PATHOPHYSIOLOGY; PSYCHOPHARMACOLOGY; REVIEW; SWEAT GLAND DISEASE; SYSTEMATIC REVIEW;

ADULT; AGED; ALCOHOL DRINKING; ALCOHOL-RELATED DISORDERS; CLINICAL TRIALS; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRUCTOSE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; PROBABILITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 4444370811     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.5.751     Document Type: Review

References (45)

1. Manwell LB, Fleming MF, Johnson K, Barry KL. Tobacco, alcohol, and drug use in a primary care sample: 90-day prevalence and associated factors. J. Addict. Dis. 17, 67-81 (1998).
2. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N. Engl. J. Med. 348,1786-1795 (2003).
3. American Psychiatric Association. Substance-related disorders. In: Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text revision. American Psychiatric Association, Washington DC, USA 191-223 (2000).
4. Johnson BA, Ait-Daoud N, Bowden CL et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361, 1677-1685 (2003). First demonstration that topiramite is an effective treatment for alcohol dependence based upon a proof-of-concept, randomized, double-blind, placebo-controlled trial
5. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J. Neurosci. 22, 3332-3337 (2002).
6. Ortiz J, Fitzgerald LW, Charlton M et al. Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 21,289-298 (1995).
7. Boehm SL II, Piercy MM, Bergstrom HC, Phillips TJ. Ventral tegmental area region governs GABAg receptor modulation of ethanol-stimulated activity in mice. Neuroscience 115, 185-200 (2002).
8. Kohl RR, Katner JS, Chernet E, McBride WJ. Ethanol and negative feedback regulation of mesolimbic dopamine release in rats. Psychopharmacology 139, 79-85 (1998).
9. Melis M, Camarini R, Ungless MA, Bonci A. Long-lasting potentiation of GABAeigic synapses in dopamine neurons after a single in vivo ethanol exposure. J. Neurosci. 22, 2074-2082 (2002).
10. Dodd PR, Beckmann AM, Davidson MS, Wilce PA. Glutamate-mediated transmission, alcohol, and alcoholism. Neurochem. Int. 37, 509-533 (2000).
11. Morrisett RA, Swartzwelder HS. Attenuation of hippocampal long-term potentiation by ethanol: a patch-damp analysis of glutamatergic and GABAergic mechanisms. J. Neurosci. 13,2264-2272 (1993).
12. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674, 82-90 (1995).
13. Raimo EB, Schuckit MA. Alcohol dependence and mood disorders. Addict. Behav. 23, 933-946 (1998).
14. Senay EC. Drug abuse and public health. A global perspective. Drug Saf. 6(Suppl. 1), 1-65 (1991).
15. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topirarnate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41(Suppl. 1),S3-S9(2000). Overview of the discovery, development, and pharmacological properties of topiramate.
16. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in marine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41(Suppl. 1), S17-S20 (2000).
17. Schiffer WK, Gerasimov MR, Marsteller DA et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 42, 196-198 (2001). Important demonstration that topiramate can attenuate nicotine-induced increases in midbrain dopamine levels. Since the majority of abused drugs have been shown to increase midbrain dopamine levels, this finding -would suggest that topiramate might have utility in treating a wide variety of substance use-related disorders.
18. Mueller TI, Stout RL, Rudden S et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin. Exp. Res. 21, 86-92 (1997).
19. Malcolm R, Myrick H, Brady KT, Ballenger JC. Update on anticonvulsants for the treatment of alcohol withdrawal. Am. J. Addict. 10(Suppl.), 16-23 (2001). Synopsis of the effects of anticonvulsants in the treatment of alcohol withdrawal Notably, tails work includes results from the testing of new anticonvulsants.
20. Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 32, 107-109 (1999).
21. Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt LG, Heinz A. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry 34, 66-72 (2001).
22. Swift RM. Medications and alcohol craving. Alcohol Res. Health 23, 207-213 (1999).
23. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge eating disorder with topiramate: a clinical case series. J. Clin. Psychiatry 61, 368-372 (2000).
24. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. 31, 29-46 (1996).
25. Garnett WR. Qinical pharmacology of topiramate: a review. Epilepsia 41(Suppl. 1), S61-S65 (2000).
26. Rosenfeld WE, Liao S, Kramer LD et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38, 324-333 (1997).
27. Sachdeo RC, Sachdeo SK, Levy RH et al Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43, 691-696 (2002).
28. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 37, 774-780 (1996).
29. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44, 540-549 (2003).
30. Doose DR, Kohl KA, Desai-Krieger D, Natarajan J, van Kammen DP. No clinically significant eflect of topiramate on haloperidol plasma concentration. Poster presented at the European College of Neuropsychopharmacology, London, UK (1999).
31. Doose DR, Kohl KA, Desai-Krieger D, Natarajan J, van Kammen DE No significant effect of topiramate on lithium serum concentration. Poster presented at the World Congress of Psychiatry, Hamburg, Germany (1999).
32. Storey JR, Calder CS, Hart DE, Potter DL Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41, 968-975 (2001).
33. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin. J. Pain 19, 59-68 (2003).
34. Roy Chengappa KN, Levine J, Rathore D, Parepally H, Atzen R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur. Psychiatry 16, 186-190 (2001).
35. Bray GA, Hollander P, Klein S et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 11,722-733 (2003).
36. McElroy SL, Arnold LM, Shapira NA et al. Topiramate in the treatment of binge eating disorder associated with obesity, a randomized, placebo-controlled trial. Am. J. Psychiatry 160,255-261 (2003). Important demonstration of topiramate's ability to reduce -weight sad binge eating behaviors. Study suggests that topiramate may be useful in treating impulse dyscontrol behaviors other than alcohol or drag dependence.
37. Biton V, Edwards KR, Montouris GD et al. Topiramate titration and tolerability. Ann. Pharmacother. 35,175-179 (2001).
38. Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE. Topiramate-induced nephrolithiasis. J. Endourol. 16,229-231 (2002).
39. Ben-Zeev B, Watemberg N, Auganen A et al. Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J. Child Neurol. 18,254-257 (2003).
40. Dodson WE, Kamin M, Kraut L, Olson WH, Wu SC. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann. Pharmacother. 37, 615-620 (2003).
41. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical setting? J. Stud. Alcohol 423-432 (1995).
42. Fawcett J, Epstein P, Fiester SJ, Ekin I, Autry JH. Cinical management-imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol. Bull. 23, 309-324 (1987).
43. Bohn MJ, Barton BA, Barron KE. Psychometric properties and validity of the obsessive-compulsive drinking scale. Alcohol Clin. Exp. Res. 20, 817-823 (1996).
44. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. Phamacopsychiatry 37, 37-40 (2004). Small open-label study showing that topiramate is well tolerated and might have utility in treating alcohol-dependent individuals with comorbid psychiatric disorder.
45. Anton RF. Pharmacologic approaches to the management of alcoholism. J. Clin. Psychiatry 62(Suppl. 20), 11-17 (2001).